NEWTOWN, Pa.--(BUSINESS WIRE)--Synerx Pharma, LLC announced today that it has received final U.S. Food and Drug Administration (FDA) approval for the Company’s Abbreviated New Drug Application (ANDA) for Ciclopirox topical solution, 8%. Synerx’s product is a generic equivalent of Dermik Laboratories’ prescription product Penlac®, a topical ciclopirox treatment for nail fungus. Sales of Penlac® in the U.S. exceeded $85 million in 2006.
